Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Future Healthc J ; 10(1): 78-81, 2023 Mar.
Article in English | MEDLINE | ID: mdl-37786500

ABSTRACT

Reflection on professional practice (either individually or in dialogue with peers or seniors) will often focus on doctors' skills. This approach emphasises compliance and competence. This paper suggests that an alternative and useful lens for professional reflection and development can be drawn from the framework of virtue ethics to encourage consideration of the ultimate purpose of medicine, and the character or virtues needed to be a good doctor. This alternative approach supports doctors to reflect on and develop their virtues, including practical wisdom, which orchestrates the doctor's skills and virtues. This emphasis on purpose and character within professional reflection promotes excellence, rather than just competency, and engages with what motivated most doctors to enter medicine.

2.
Curr Oncol ; 30(2): 1673-1682, 2023 01 30.
Article in English | MEDLINE | ID: mdl-36826089

ABSTRACT

BACKGROUND: Home-based and supervised prehabilitation programmes are shown to have a positive impact on outcomes in patients with oesophago-gastric (OG) cancer. The primary aim of this study was to establish the feasibility of delivering a digital prehabilitation service. METHODS: Patients undergoing treatment for OG cancer with curative intent were recruited into the study. During the COVID-19 pandemic, patients were offered a digital prehabilitation service. Following the lifting of COVID-19 restrictions, patients were also offered both a hybrid clinic-based in-person service and a digital service. Implementation and clinical metrics from the two prehabilitation models were compared. RESULTS: 31 of 41 patients accepted the digital service (75%). Of the people who started the digital programme, 3 dropped out (10%). Compliance with the weekly touchpoints was 86%, and the median length of programme was 12 weeks. Twenty-six patients enrolled in the in-person service. Two patients dropped out (10%). Average compliance to weekly touchpoints was 71%, and the median length of programme was 10 weeks. In the digital group, sit to stand (STS) increased from 14.5 (IQR 10.5-15.5) to 16 (IQR 16-22); p = 0.02. Median heart rate recovery (HRR) increased from 10.5 (IQR 7.5-14) to 15.5 (IQR 11-20) bpm; p = 0.24. There was a significant drop in distress (median 3 (IQR 0-5) to 1 (IQR 0-2); p = 0.04) and a small drop in anxiety (median 3 (0-5) to 2 (0-3); p = 0.22). There was no difference in the postoperative complication rate and length of hospital stay between the two groups. DISCUSSION: This study has shown that digital prehabilitation can be delivered effectively to patients with OG cancer, with high engagement and retention rates. We observed improvements in some physical and psychological parameters with the digital service, with comparable clinical outcomes to the in-person service.


Subject(s)
COVID-19 , Stomach Neoplasms , Humans , Preoperative Exercise , Feasibility Studies , Pandemics , Preoperative Care
4.
Future Oncol ; 10(16): 2555-60, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24877667

ABSTRACT

AIMS: Studies of circulating tumor cells (CTCs) have generally recruited individuals with newly diagnosed metastatic cancer, with recent data also indicating their prognostic value in the adjuvant setting. Their role in dying patients has not been established. EXPERIMENTAL: CTCs were measured in 43 individuals with metastatic breast cancer estimated to have less than 6 months to live who had exhausted standard therapeutic options. RESULTS: Those with a CTC count of ≤ 100 had a median of 182 days to live, compared with those with a CTC count of >100 who had a median of 17 days until death (p = 0.009, log rank, HR: 3.1, 95% CI: 1.4-7.3). CONCLUSION: A CTC count of >100 is associated with imminent death. Provided external validity is demonstrated, such information would be useful for patients and their families who often request specific prognostic clarity and could improve the quality of end-of-life care.


Subject(s)
Biomarkers, Tumor/blood , Breast Neoplasms/blood , Neoplastic Cells, Circulating/pathology , Prognosis , Adult , Aged , Aged, 80 and over , Breast Neoplasms/epidemiology , Breast Neoplasms/pathology , Cell Count , Female , Humans , Kaplan-Meier Estimate , Life Expectancy , Middle Aged , Neoplasm Metastasis
5.
Neurosci Lett ; 393(2-3): 237-42, 2006 Jan 30.
Article in English | MEDLINE | ID: mdl-16256273

ABSTRACT

Descending modulation of spinal processing plays an important role in chronic pain states. Monoamine pathways comprise a major component of descending controls from the brainstem to the spinal cord. Recent emphasis has been on facilitatory actions mediated by the 5-HT3 receptor. We investigated the effects of spinally administered ondansetron, a selective 5-HT3 receptor antagonist, on electrical- and natural-evoked dorsal horn (DH) neuronal responses in a rat model of cancer-induced bone pain (CIBP). Injection of MRMT-1 cells into the tibiae of Sprague-Dawley rats was used to model CIBP, whilst sham-operated rats were injected with the cell medium alone. Behavioural testing at regular intervals monitored the development of mechanical allodynia, cold allodynia, and ambulatory-evoked pain. In vivo electrophysiology experiments were carried out 15-17 days after surgery, when there were significant behavioural and neuronal alterations in the cancer animals. Spinally administered ondansetron (10, 50, and 100 microg) had no effect on electrical-evoked neuronal responses, but significantly reduced mechanical- and thermal-evoked responses in both the groups of animals. Furthermore, the effects of ondansetron were significantly greater in cancer animals compared to shams. These results therefore suggest a role for descending serotonergic facilitation in CIBP.


Subject(s)
Bone Diseases/physiopathology , Disease Models, Animal , Neoplasms/physiopathology , Pain/physiopathology , Serotonin/metabolism , Animals , Behavior, Animal , Cell Line, Tumor , Dose-Response Relationship, Drug , Evoked Potentials/drug effects , Evoked Potentials/physiology , Evoked Potentials/radiation effects , Functional Laterality , Male , Motor Activity/physiology , Neoplasms/complications , Neoplasms/etiology , Ondansetron/administration & dosage , Pain/etiology , Pain Measurement/methods , Physical Stimulation/methods , Posterior Horn Cells/drug effects , Posterior Horn Cells/physiopathology , Posterior Horn Cells/radiation effects , Rats , Rats, Sprague-Dawley , Reaction Time/physiology , Rotarod Performance Test/methods , Serotonin Antagonists/administration & dosage , Temperature , Time Factors
6.
J Pain ; 6(12): 837-45, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16326372

ABSTRACT

UNLABELLED: Morphine is one of the main analgesics in cancer-induced bone pain (CIBP). To investigate the efficacy of morphine in CIBP and alteration in dorsal horn pathophysiology, systemic morphine was administered (3 mg/kg) bi-daily between days 11 and 15 after MRMT-1 carcinoma cell injections (compared with a single injection (3 mg/kg) of morphine on day 15, and acute spinal morphine (0.1, 1, 10 microg/50 microL). The chronic systemic morphine schedule significantly attenuated pain behavior (von Frey 15 g; P < .01) to a greater extent than acute systemic morphine (von Frey 15 g; P < .05). In vivo electrophysiology (day 15 chronic systemic morphine) showed an attenuation of hyperexcitable wide dynamic range (WDR) neurons, but the abnormal raised WDR to nociceptive specific neuronal ratio remained. Acute spinal morphine attenuated electrical and natural WDR neuronal response in shams at a lower dose (1 microg) compared with cancer (10 microg). Chronic morphine is more effective at attenuating pain-related behaviors than single doses, although the dorsal horn retains a pathophysiologic characterization. PERSPECTIVE: This study confirms the resemblance of the rat model to human CIBP with respect to the efficacy of morphine and further suggests that adjuvant therapy is required to reverse the dorsal horn pathophysiology.


Subject(s)
Bone Neoplasms/complications , Morphine/administration & dosage , Nociceptors/drug effects , Pain, Intractable/drug therapy , Pain, Intractable/physiopathology , Posterior Horn Cells/drug effects , Action Potentials/drug effects , Action Potentials/physiology , Analgesics, Opioid/administration & dosage , Anesthesia, Intravenous , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Bone Neoplasms/secondary , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Injections, Spinal , Male , Mammary Neoplasms, Experimental/complications , Mammary Neoplasms, Experimental/secondary , Nociceptors/physiopathology , Pain Measurement , Pain Threshold/drug effects , Pain Threshold/physiology , Pain, Intractable/etiology , Physical Stimulation , Posterior Horn Cells/physiopathology , Rats , Rats, Sprague-Dawley , Treatment Outcome , Tumor Cells, Cultured/transplantation
7.
Anesthesiology ; 102(1): 132-40, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15618797

ABSTRACT

BACKGROUND: Cancer-induced bone pain is a major clinical problem for which current treatments lack full efficacy. Gabapentin is licensed for use in neuropathic pain yet is also effective against inflammatory stimuli in animals. METHODS: A rat model of cancer-induced bone pain using the MRMT-1 cell line injected into the tibia was established to investigate the efficacy of acute (10, 30, 100 mg/kg) and chronic (30 mg/kg) systemic gabapentin on electrophysiological superficial dorsal horn neuronal responses to natural and noxious electrical stimuli, as well as on pain-related behavior. RESULTS: In electrophysiological studies gabapentin worked both acutely (100 mg/kg) and chronically (30 mg/kg) to normalize the hyperexcitable superficial dorsal horn neuronal response, significantly reducing electrical-evoked and mechanical-evoked but not thermal-evoked responses. The behavioral study showed that chronic gabapentin (30 mg/kg) significantly attenuated pain behavior in MRMT-1 rats, restoring responses to preoperative baseline degrees, and that this attenuation was accompanied by a reversion to normal (non-MRMT-1) wide-dynamic-range: nociceptive specific superficial dorsal horn neuronal profiles. CONCLUSIONS: Pain-related behavior in this rat model of cancer-induced bone pain is strongly linked to hyperexcitability of a population of superficial dorsal horn neurones. Gabapentin normalizes the cancer-induced bone pain induced dorsal horn neuronal changes and attenuates pain behavior. It may therefore provide a novel clinical treatment for cancer-induced bone pain.


Subject(s)
Amines/pharmacology , Analgesics/pharmacology , Behavior, Animal/drug effects , Behavior, Animal/physiology , Bone Neoplasms/complications , Cyclohexanecarboxylic Acids/pharmacology , Neurons/drug effects , Pain/psychology , Spinal Cord/drug effects , gamma-Aminobutyric Acid/pharmacology , Animals , Cell Line, Tumor , Dose-Response Relationship, Drug , Electric Stimulation , Electrophysiology , Evoked Potentials/drug effects , Gabapentin , Male , Neoplasm Transplantation , Osteotomy , Pain/etiology , Pain/physiopathology , Pain Measurement/drug effects , Physical Stimulation , Rats , Rats, Sprague-Dawley , Spinal Cord/cytology , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...